Title : Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.

Pub. Date : 2017 Jun

PMID : 28494686






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 INTRODUCTION: Selexipag is the first oral, non-prostanoid, selective prostacyclin receptor (IP receptor) agonist, approved for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients. selexipag prostaglandin I2 receptor Homo sapiens